Williams-Sonoma’s (NYSE: WSM) stock broke out of a trading range earlier this year to confirm its uptrend remains intact. The market reconfirmed the breakout following the Q2 earnings release, signaling the next leg of the uptrend is at hand. How high the stock gets depends on several factors, incl.... |
Good MorningU.S. stocks edged lower Wednesday as a slightly hotter-than-expected headline PCE inflation reading renewed pressure on rate-sensitive assets. The Dow snapped a three-session winning streak, while broad-market ETFs and small caps declined. Housing also remained a concern after July, as new-home sales fell 10.5% while mortgage rates remained elevated near 6.7%.
NVIDIA delivered another record quarter, with revenue of $96.2 billion, up 106% year over year, led by $89 billion in data-center sales. Its $108 billion third-quarter revenue outlook exceeded Wall Street expectations, but shares slipped in extended trading as investors weighed AI-spending sustainability and long-term competitive risks.
After the bell, enterprise software and cybersecurity earnings lifted several technology names. Salesforce topped expectations, raised its full-year outlook, and expanded its Anthropic partnership, sending shares sharply higher. Okta also rallied after beating estimates and lifting guidance as demand for identity security tied to agentic AI strengthened, while CrowdStrike rose after topping earnings and revenue expectations. HP raised its full-year EPS and free-cash-flow outlook after third-quarter revenue climbed 12.5%, and Synopsys increased its full-year forecast following strong quarterly results. Featured: Insiders caught red-handed in the predictions market (Ad) 
| Consumer Discretionary | |
Williams-Sonoma’s (NYSE: WSM) stock broke out of a trading range earlier this year to confirm its uptrend remains intact. The market reconfirmed the breakout following the Q2 earnings release, signaling the next leg of the uptrend is at hand. How high the stock gets depends on several factors, incl... Read the Full Story |
| From Our Partners | | Gold just broke another record - a classic flight-to-safety signal that the smartest money on Wall Street is already acting on. With the NASDAQ pricing in optimism over fundamentals and global tensions continuing to rise, a market correction could arrive without warning.
Our research team just released a free crash-protection guide identifying which stocks and sectors can hold strong even when the broader market crumbles. | | Download your free crash protection guide today |
| Materials | |
The global semiconductor supply chain has a critical vulnerability that traces back to a single raw material. Used in everything from advanced military radar to next-generation artificial intelligence (AI) hardware, gallium is a critical material for modern technology. With foreign monopolies activ... Read the Full Story |
| Technology | |
The wearable technology space is quietly undergoing a structural shift. Forecasts project that the global wearables market will surpass $100 billion in 2026 and reach roughly $230 billion by 2033. Investors seeking the next wave of hardware capitalization are closely watching Oura Health.
Oura is r... Read the Full Story |
| From Our Partners | | Every afternoon at 2:00 PM Eastern, roughly $3.5 billion in institutional money flows into the market as pension funds and 401(k) contributions get deployed before the close.
Researchers at Duke, Stanford, Notre Dame, and the Nasdaq Economic Advisory Board have studied this pattern. During one volatile week in June, a $1,000 trade set at 2:00 PM settled by 4:00 PM five days in a row, and the full month produced $2,016 in net income on a single contract. | | Watch the full 2 PM income breakdown before access closes |
| Consumer Discretionary | |
Say what you like about Elon Musk, the man knows how to command an audience—this month brought his latest flourish, a promise that Tesla Inc. (NASDAQ: TSLA) will soon show off a hovering version of its long-awaited Roadster, using rocket-style thruster technology to lift the sports car clean off th... Read the Full Story |
| Technology | |
Photronics (NASDAQ: PLAB) is a critical cog in the AI ecosystem because of what it makes. It isn’t a semiconductor company per se, but makes photomasks, the blueprints from which nearly all semiconductors are made.
The company is tight-lipped about client details but it is understood to be well en... Read the Full Story |
| From Our Partners | | Every afternoon at 2:00 PM Eastern, roughly $3.5 billion in institutional capital flows into the market as pension funds and major players settle their daily orders before the 4:00 PM close.
During the market turmoil of March 11 through March 18, a basic $1,000 trade placed at 2:00 PM each day would have generated results ranging from $136 to $219 by the closing bell, according to research shared by Nate Tucci.
The full breakdown of this afternoon trading window is available now in a complete presentation. | | Watch the complete 2 PM Income presentation before access closes |
| Markets | |
Before the OpenAI IPO materializes and while Anthropic has yet to go public, it may be tough for investors to cite a single company as the face of AI. Still, NVIDIA Corp. (NASDAQ: NVDA) is as good a candidate as any: as the largest publicly traded firm in the world and an undisputed leader in the s... Read the Full Story |
| Technology | |
Palantir Technologies (NASDAQ: PLTR) has become a stock behavioral psychologists would love. That's because every data point splits investors into the same two camps. The bulls believe Palantir is a rare one-of-one stock that has much more runway than the current price suggests. The bears see PLTR ... Read the Full Story |
| Technology | |
The artificial intelligence (AI) computing sector is fracturing. For years, one hardware architecture dictated the pace of AI advancement. Today, hyperscalers are rewriting that narrative by bringing silicon development in-house. Newly released benchmark results around the Hot Chips 2026 conference... Read the Full Story |
| Markets | |
With market concentration remaining near all-time highs, achieving true portfolio diversification means that today’s investors need to look beyond the major indices. That entails funds that provide exposure to international value stocks, small caps, and emerging markets.
For investors seeki... Read the Full Story |
| Industrials | |
In an earnings season where many companies delivered standout results, Honeywell Aerospace (NASDAQ: HONA) stood out for the wrong reasons. The company delivered its first earnings report as a stand-alone company, and the results were underwhelming.
Net income was down 70%, adjusted earnings per sh... Read the Full Story |
| Thursday's Early Bird Stock Of The Day Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts. | Should I Buy Thermo Fisher Scientific Stock? TMO Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Thermo Fisher Scientific was last updated on Wednesday, October 07, 2026 at 6:13 PM.
Thermo Fisher Scientific Bull Case -
Thermo Fisher Scientific Inc. recently reported strong third-quarter results, beating analyst expectations with earnings per share of $6.03 against a consensus of $5.71 and revenue of $11.99 billion, which exceeded the expected $11.71 billion, demonstrating robust operational performance and demand for its life sciences solutions.
-
The company has raised its full-year 2026 earnings per share guidance to a range of $24.93 to $25.33, signaling management confidence in continued growth, while the stock currently trades at $660.97, reflecting a 52-week high of $694.33 and indicating strong market momentum and investor interest in its trajectory.
-
Thermo Fisher Scientific Inc. is expanding its clinical research and drug development capabilities, recently signing a Study Start-Up Agreement with Quantum BioPharma to support a Phase 2 multiple sclerosis trial, which reinforces its role as a key partner in the biopharma sector and supports its Laboratory Products and Biopharma Services segment.
-
Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average price target of $633.13, while recent upgrades from firms like HSBC, which raised its rating to Strong Buy, and Deutsche Bank, which set a $720 price target, suggest that institutional investors see significant upside potential in the stock.
-
The company maintains a solid financial position with a current ratio of 1.55 and a quick ratio of 1.18, indicating sufficient liquidity to cover short-term obligations, while its debt-to-equity ratio of 0.74 suggests a manageable leverage level that supports long-term stability and growth initiatives.
Thermo Fisher Scientific Bear Case -
Thermo Fisher Scientific Inc. trades at a price-to-earnings ratio of 35.56, which is significantly higher than the broader market average, making the stock sensitive to any changes in growth expectations, interest rates, or market sentiment, as evidenced by a recent 4.2% drop that erased approximately $10 billion in market value in a single session.
-
Insider selling has been notable in recent months, with CEO Marc N. Casper and other executives selling a combined 73,768 shares valued at $44,122,820 in the last ninety days, which may signal a lack of confidence from company leadership or a desire to diversify personal holdings at current price levels.
-
The company faces macroeconomic uncertainty and foreign-exchange exposure, as noted by Zacks Research, which characterizes the outlook as balanced due to these risks, potentially impacting its international revenue streams and profitability in the North America, Europe, and Asia-Pacific regions.
-
Short interest in Thermo Fisher Scientific Inc. has increased, with shares shorted rising to 5,019,933 as of September 15, 2026, representing a 1.36% short percentage of float, indicating that some investors are betting against the stock's future performance and potentially anticipating a decline in value.
-
Some institutional investors have reduced their positions, such as S.E.E.D. Planning Group LLC, which cut its stake by 14.9% in the third quarter, and Citigroup, which lowered its rating from Buy to Underperform in September 2026, suggesting that certain market participants are taking profits or reassessing the stock's valuation relative to its growth prospects.
| | View Today's Stock Pick |
|
| |
|
|
